Johnson & Johnson (NYSE:JNJ) Barclays Global Healthcare Conference March 14, 2023 10:15 AM ET Company Participants Aldo Denti - Company Group Chairman, DePuy Synthes The Orthopedic Company Peter Menziuso - Company Group Chairman, Johnson & Johnson Vision Conference Call Participants Matt Miksic - Barclays Operator Matt Miksic So good morning, everybody. My name is Matt Miksic, I am the Medical Device Analyst here in US for Barclays. I am very pleased to have with us today J&J, from J&J, Aldo Denti, Company ...

Johnson & Johnson (NYSE:JNJ) Cowen 43rd Annual HealthCare Conference March 7, 2023 11:10 AM ET Company Participants Joe Wolk - EVP and CFO Jessica Moore - VP, IR Conference Call Participants Josh Jennings - Cowen Josh Jennings Josh Jennings from Cowen Medical Devices team. We're moving right through the medical devices track, but we are incorporating some medical device part of a consumer hybrid into this track. And thankfully, with the executive team from Johnson & Johnson. We have Executive Vice President ...

As filed with the Securities and Exchange Commission on March 3, 2023. Registration No. 333-269115 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kenvue Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2844 88-1032011 (I.R.S. Employer Identification Number) 199 G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kenvue Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) As filed with the Securities and Exchange Commission on February 3, 2023. Registration No. 333-269115 (Primary Standard Industrial Classification Code Number) Delaware 2844 88-1032011 (I.R.S. Employer Identification Number) 19 ...

Johnson & Johnson (NYSE:JNJ) Q4 2022 Results Conference Call January 24, 2023 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman and CEO Joe Wolk - EVP and CFO Conference Call Participants Terence Flynn - Morgan Stanley David Risinger - SVB Securities Larry Biegelsen - Wells Fargo Chris Schott - JP Morgan Matt Miksic - Barclays Chris Shibutani - Goldman Sachs Louise Chen - Cantor Fitzgerald Operator Good morning and welcome to Johnson & Johnson’s Fourth Quarter 2022 Earnings Con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended October 2, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of incorpor ...

Good morning and welcome to Johnson & Johnson's 3rd Quarter 2022 Earnings Conference Call. All participants will be in a listener mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach the operator. I will now turn the conference call over to Johnson & Johnson. You may begin. Please note that today's meeting may in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 3, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of incorporati ...

All participants will be in a listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach an operator. I would now like to turn the conference call over to Johnson & Johnson. You may begin. Please note that today's meeting may include forward-looking statements relating to, among other things, the company's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 3, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of incorporat ...